BML, Inc. operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BML with three other
pharmaceutical manufacturers in Asia:
Zhejiang DA Diagnostics Co Ltd
sales of 705.25 million Chinese Renmimbi [US$115.03 million]
of which 59%
was Medical Diagnostic Service),
Falco Sd Holdings Company Limited
(60.83 billion Japanese Yen [US$589.42 million]
of which 46%
was Clinical Testing), and
Miraca Holdings Incorporated
(175.39 billion Japanese Yen [US$1.70 billion]
of which 62%
was Clinical & Other Diagnostic).
BML reported sales of ¥92.20 billion (US$893.43 million)
March of 2012.
increase of 14.2%
versus 2011, when the company's sales were ¥80.76 billion.
Sales at BML have increased during each of the previous five years
(and since 2007, sales have increased a total of 28%).
Sales of Clinical Test saw an increase
14.7% in 2012, from
¥77.33 billion to ¥88.73 billion.